MREO
Income statement / Annual
Last year (2024), Mereo BioPharma Group plc's total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2024, Mereo BioPharma Group plc's net income was -$43.25 M.
See Mereo BioPharma Group plc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$10.00 M |
$0.00 |
$49.21 M |
$0.00 |
$0.00 |
$0.00 |
-$3.29 M |
$0.00 |
| Cost of Revenue |
$0.00
|
$2.57 M
|
-$257.44 K
|
$24.17 M
|
$2.05 M
|
$2.01 M
|
$22.70 M
|
$34.61 M
|
$24.56 M
|
| Gross Profit |
$0.00
|
$7.43 M
|
$257.44 K
|
$25.04 M
|
-$2.05 M
|
-$2.01 M
|
-$22.70 M
|
-$37.89 M
|
-$24.56 M
|
| Gross Profit Ratio |
0
|
0.74
|
0
|
0.51
|
0
|
0
|
0
|
11.53
|
0
|
| Research and Development Expenses |
$20.93 M
|
$17.42 M
|
$30.75 M
|
$31.80 M
|
$20.96 M
|
$30.12 M
|
$22.70 M
|
$34.61 M
|
$24.56 M
|
| General & Administrative Expenses |
$26.43 M
|
$18.42 M
|
$0.00
|
$21.50 M
|
$0.00
|
$0.00
|
$12.50 M
|
$10.70 M
|
$11.62 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$26.43 M
|
$18.42 M
|
$23.18 M
|
$21.50 M
|
$25.16 M
|
$18.28 M
|
$12.50 M
|
$10.70 M
|
$11.62 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$293.33 K
|
$0.00
|
| Operating Expenses |
$47.36 M
|
$35.84 M
|
$53.92 M
|
$53.30 M
|
$46.13 M
|
$48.40 M
|
$12.50 M
|
$10.70 M
|
$11.62 M
|
| Cost And Expenses |
$47.36 M
|
$38.42 M
|
$53.67 M
|
$77.47 M
|
$48.18 M
|
$50.41 M
|
$35.21 M
|
$45.30 M
|
$36.18 M
|
| Interest Income |
$3.04 M
|
$2.13 M
|
$696.00 K
|
$1.38 K
|
$44.00 K
|
$377.00 K
|
$306.83 K
|
$826.86 K
|
$195.14 K
|
| Interest Expense |
$1.37 M
|
$2.88 M
|
$3.36 M
|
$5.22 M
|
$6.38 M
|
$3.50 M
|
$2.36 M
|
$1.09 M
|
$179.77 K
|
| Depreciation & Amortization |
$1.09 M
|
$1.06 M
|
$895.50 K
|
$866.47 K
|
$2.05 M
|
$2.01 M
|
$37.80 K
|
$36.08 K
|
$32.94 K
|
| EBITDA |
-$40.80 M |
-$26.06 M |
-$39.98 M |
$25.49 M |
-$203.41 M |
-$44.57 M |
-$34.86 M |
-$44.44 M |
-$38.41 M |
| EBITDA Ratio |
0
|
-2.61
|
0
|
0.52
|
0
|
0
|
0
|
13.53
|
0
|
| Operating Income Ratio |
0
|
-2.84
|
0
|
-0.57
|
0
|
0
|
0
|
13.79
|
0
|
| Total Other Income/Expenses Net |
$4.11 M
|
-$1.58 M
|
$9.21 M
|
$47.48 M
|
-$165.27 M
|
-$2.04 M
|
-$2.10 M
|
-$1.65 M
|
$2.46 M
|
| Income Before Tax |
-$43.25 M
|
-$30.00 M
|
-$44.46 M
|
$19.22 M
|
-$213.45 M
|
-$52.46 M
|
-$37.31 M
|
-$46.95 M
|
-$33.72 M
|
| Income Before Tax Ratio |
0
|
-3
|
0
|
0.39
|
0
|
0
|
0
|
14.29
|
0
|
| Income Tax Expense |
$0.00
|
-$532.00 K
|
-$2.34 M
|
$2.05 M
|
-$3.62 M
|
-$8.00 M
|
-$5.28 M
|
-$8.15 M
|
-$5.33 M
|
| Net Income |
-$43.25 M
|
-$29.47 M
|
-$42.12 M
|
$17.17 M
|
-$209.83 M
|
-$44.45 M
|
-$32.03 M
|
-$38.80 M
|
-$28.39 M
|
| Net Income Ratio |
0
|
-2.95
|
0
|
0.35
|
0
|
0
|
0
|
11.81
|
0
|
| EPS |
-0.29 |
-1100.22 |
-1750.35 |
749.65 |
-16503.3 |
-12902.58 |
-14352.87 |
-19003.8 |
-19553.91 |
| EPS Diluted |
-0.29 |
-1100.22 |
-1750.35 |
749.65 |
-16503.3 |
-12902.58 |
-14352.87 |
-19003.8 |
-19553.91 |
| Weighted Average Shares Out |
$147.92 M
|
$131.89 M
|
$120.64 M
|
$116.73 M
|
$67.79 M
|
$17.87 M
|
$14.23 M
|
$13.80 M
|
$8.96 M
|
| Weighted Average Shares Out Diluted |
$147.92 M
|
$131.89 M
|
$120.64 M
|
$116.73 M
|
$67.79 M
|
$17.88 M
|
$14.23 M
|
$13.80 M
|
$8.96 M
|
| Link |
|
|
|
|
|
|
|
|
|
